文献速递基础与转化研究临床试验与 GCP组学、生物样本库与精准医学

循环肿瘤DNA指导转移性乳腺癌临床试验入组与精准肿瘤学:一项队列研究

Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
PubMed 文献 · PLoS Med · 2020-10-01

该前瞻性队列研究纳入234例转移性乳腺癌患者,采用ddPCR和靶向测序实时检测血浆ctDNA,评估其指导临床管理的可行性。基线ddPCR和靶向测序分别检出34.2%和39.0%的可操作突变,联合系列检测达44.4%。ctDNA结果改变了40例患者的临床管理,包括直接招募20例进入临床试验。

要点

  • ctDNA检测在转移性乳腺癌中可行,能实时指导临床试验入组。
  • 基线ddPCR和靶向测序可操作突变检出率分别为34.2%和39.0%。
  • ctDNA水平升高与总生存期较差相关。

核心结论

  • 前瞻性ctDNA检测是指导转移性乳腺癌临床试验入组和患者管理的实用可行方法。

研究设计与样本

  • 前瞻性队列研究,2015年6月至2018年10月在澳大利亚墨尔本Peter MacCallum癌症中心纳入234例转移性乳腺癌患者,中位年龄54岁,中位随访15个月(范围1–46)。
  • 所有患者入组时样本实时分析体细胞突变,67例(28.6%)根据临床偏好进行纵向血浆检测。
  • 采用多重微滴数字PCR检测PIK3CA、ESR1、ERBB2和AKT1热点突变,部分样本行靶向panel测序和低覆盖全基因组测序。

主要发现

  • ddPCR和靶向panel测序在基线分别检出80/234(34.2%)和62/159(39.0%)患者至少一个可操作突变。
  • 联合基线和系列ctDNA检测,104/234(44.4%)患者检出可操作改变。
  • 对27例患者行LC-WGS,发现包括11q13.3(含CCND1)在内的反复扩增区域。
  • ctDNA水平升高与较差的总生存期相关(ddPCR、靶向测序或LC-WGS评估均如此)。
  • ctDNA结果改变了40例患者的临床管理,包括直接招募20例患者进入临床试验。

临床怎么用

  • 可采用ddPCR或靶向测序对转移性乳腺癌患者进行血浆ctDNA检测,以识别可操作突变并指导临床试验入组。
  • 系列ctDNA检测可用于重复分子谱分析或疾病监测。

局限性

  • 研究在单中心进行。
  • 31.3%的参与者失访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metastatic breast cancer (mBC) is a heterogenous disease with increasing availability of targeted therapies as well as emerging genomic markers of therapeutic resistance, necessitating timely and accurate molecular characterization of disease. As a minimally invasive test, analysis of circulating tumour DNA (ctDNA) is well positioned for real-time genomic profiling to guide treatment decisions. Here, we report the results of a prospective testing program established to assess the feasibility of ctDNA analysis to guide clinical management of mBC patients. METHODS AND FINDINGS: Two hundred thirty-four mBC patients (median age 54 years) were enrolled between June 2015 and October 2018 at the Peter MacCallum Cancer Centre, Melbourne, Australia. Median follow-up was 15 months (range 1-46). All patient samples at the time of enrolment were analysed in real time for the presence of somatic mutations. Longitudinal plasma testing during the course of patient management was also undertaken in a subset of patients (n = 67, 28.6%), according to clinician preference, for repeated molecular profiling or disease monitoring. Detection of somatic mutations from patient plasma was performed using a multiplexed droplet digital PCR (ddPCR) approach to identify hotspot mutations in PIK3CA, ESR1, ERBB2, and AKT1. In parallel, subsets of samples were also analysed via next-generation sequencing (targeted panel sequencing and low-coverage whole-genome sequencing [LC-WGS]). The sensitivity of ddPCR and targeted panel sequencing to identify actionable mutations was compared. Results were discussed at a multidisciplinary breast cancer meeting prior to treatment decisions. ddPCR and targeted panel sequencing identified at least 1 actionable mutation at baseline in 80/234 (34.2%) and 62/159 (39.0%) of patients tested, respectively. Combined, both methods detected an actionable alteration in 104/234 patients (44.4%) through baseline or serial ctDNA testing. LC-WGS was performed on 27 patients from the cohort, uncovering several recurrently amplified regions including 11q13.3 encompassing CCND1. Increasing ctDNA levels were associated with inferior overall survival, whether assessed by ddPCR, targeted sequencing, or LC-WGS. Overall, the ctDNA results changed clinical management in 40 patients including the direct recruitment of 20 patients to clinical trials. Limitations of the study were that it was conducted at a single site and that 31.3% of participants were lost to follow-up. CONCLUSION: In this study, we found prospective ctDNA testing to be a practical and feasible approach that can guide clinical trial enrolment and patient management in mBC.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Zivanovic Bujak A, Weng CF, Silva MJ, et al. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study. PLoS Med. 2020. PMID: 33001984. doi:10.1371/journal.pmed.1003363

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。